Key result
Activating hepatocyte lipophagy using a synthetic adaptor protein, alpelisib, or digoxin strongly mitigated steatosis and hepatitis in a diet-induced mouse NASH model.
Why the study?
Does the induction of lipophagy using a synthetic adaptor protein, alpelisib, or digoxin mitigate steatosis and hepatitis in a diet-induced mouse NASH model?
Population
Diet-induced mouse NASH model
Design
Preclinical
Authors
Loading...
May offer lipophagy-based NASH approach; leaves open clinical translation from Level 5 evidence.
Does the induction of lipophagy using a synthetic adaptor protein, alpelisib, or digoxin mitigate steatosis and hepatitis in a diet-induced mouse NASH model?
Inducing lipophagy via synthetic adaptor proteins or clinically approved drugs like alpelisib and digoxin represents a promising therapeutic approach to prevent NASH progression.
Lewis et al. (1963) studied Nonalcoholic steatohepatitis (NASH). Lipophagy activation (synthetic adaptor protein, alpelisib, or digoxin) was evaluated on Steatosis and hepatitis progression. Activating hepatocyte lipophagy using a synthetic adaptor protein, alpelisib, or digoxin strongly mitigated steatosis and hepatitis in a diet-induced mouse NASH model.
Synapse has enriched one closely related paper. Consider it for comparative context: